Home Cart Sign in  
Chemical Structure| 18814-49-8 Chemical Structure| 18814-49-8

Structure of 18814-49-8

Chemical Structure| 18814-49-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 18814-49-8 ]

CAS No. :18814-49-8
Formula : C20H29N3O6
M.W : 407.46
SMILES Code : O=C(CC[C@H](C(N)=O)NC([C@H](C)NC(OC(C)(C)C)=O)=O)OCC1=CC=CC=C1
MDL No. :MFCD00235761
InChI Key :GBWLWWKUNXXPCZ-DZGCQCFKSA-N
Pubchem ID :7289350

Safety of [ 18814-49-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 18814-49-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 29
Num. arom. heavy atoms 6
Fraction Csp3 0.5
Num. rotatable bonds 14
Num. H-bond acceptors 6.0
Num. H-bond donors 3.0
Molar Refractivity 105.61
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

136.82 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

3.01
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.33
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.24
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.88
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.66
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.62

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.43
Solubility 1.5 mg/ml ; 0.00369 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.8
Solubility 0.0639 mg/ml ; 0.000157 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.24
Solubility 0.0233 mg/ml ; 0.0000573 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.84 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

1.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

1.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.87

Application In Synthesis of [ 18814-49-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 18814-49-8 ]

[ 18814-49-8 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 15761-38-3 ]
  • D-γ-methyl isoglutamine hydrochloride [ No CAS ]
  • [ 18814-49-8 ]
  • 3
  • [ 18814-49-8 ]
  • [ 18814-50-1 ]
YieldReaction ConditionsOperation in experiment
96% With palladium 10% on activated carbon; hydrogen; In methanol; at 20℃; for 24h; General procedure: Benzyl protected peptide was dissolved in MeOH, 10% Pd/C was added and it was subjectedto hydrogen atmosphere under 35 psi at room temperature for 24-48 h. The catalyst was thenfiltered, the solvent removed in vacuo and the residue purified by column chromatography onsilica gel.
  • 4
  • [ 67-56-1 ]
  • [ 18814-49-8 ]
  • [ 74817-55-3 ]
  • [ 123418-30-4 ]
  • 5
  • [ 15761-38-3 ]
  • [ 87137-45-9 ]
  • [ 18814-49-8 ]
  • 7
  • [ 18814-49-8 ]
  • [ 66025-93-2 ]
  • 8
  • [ 100-39-0 ]
  • [ 18814-50-1 ]
  • [ 18814-49-8 ]
  • 9
  • [ 71811-14-8 ]
  • [ 66714-34-9 ]
  • [ 18814-49-8 ]
  • 10
  • [ 80143-17-5 ]
  • [ 3392-05-0 ]
  • [ 18814-49-8 ]
  • 12
  • [ 18814-49-8 ]
  • [ 76-05-1 ]
  • [ 66025-93-2 ]
YieldReaction ConditionsOperation in experiment
100% In dichloromethane; at 20℃; for 1h; Boc-L-alanyl-D-isoglutamine benzyl ester (400 mg,0.98 mmol) was suspended in anhydrous CH2Cl2 (2 mL) and TFA (1 mL) was added. The reaction mixture was stirred at room temperature for 1 h (until the disappearance of Boc-L-Ala-D-isoGln-OBn was confirmed via TLC) and then concentratedin vacuo. The residue was purified by flash chromatographyon silica gel (CHCl3/MeOH 2:1) to yield L-Ala-D-isoGlnOBn TFA salt (414 mg, 0.98 mmol) as viscous oil in quantitative yield. Rf = 0.49 (CHCl3/MeOH 2:1). 1H NMR (MeOH-d4, 300 MHz) delta 7.36-7.30 (m, 5H, Harom), 5.13 (s,2H, CH2; Bn), 4.41 (dd, J = 5.1, 9.0 Hz, 1H, CH-alpha; isoGln), 3.87 (q, J = 7.0 Hz, 1H, CH-alpha; Ala), 2.48 (pt, J = 7.5, 7.7 Hz,2H; CH2-gamma; isoGln), 2.24-2.13 (m, 1H, CH-beta; isoGln), 2.03-1.91 (m, 1H CH-beta; isoGln), 1.44 (d, J = 7.0 Hz, 3H, CH3; Ala). 13C NMR (MeOH-d4, 75.5 MHz) delta 193.85, 192.40 (C=O), 129.61, 129.30 (CHarom), 67.56 (CH2; Bn), 53.72,50.56 (CH-alpha; Ala, isoGln), 31.42 (CH2-gamma), 28.43 (CH2-beta),18.32 (CH3; Ala). MS (ESI) m/z: [M]+ calcd for C15H22N3O4+ 308.2, found 308.1.
at 20℃; for 0.25h; Compound 5 (t-Butoxycarbonyl-L-alanyl-D-isoglutamine benzyl ester, 0.95 g, 2.42 mmols) which was obtained from Scheme-A as disclosed in Example 1.1.4 was dissolved in cold trifluoroacetic acid (10 mL) and the resulting solution was stirred at room temperature for 15 mins. Trifluoroacetic acid was then removed and the residue was triturated with Et2O to obtain L-alanyl-D-isoglutamine benzyl ester trifluoroacetate. This L-alanyl-D-isoglutamine benzyl ester trifluoroacetate was dried over NaOH pellets.
  • 13
  • [ 53759-36-7 ]
  • [ 18814-49-8 ]
  • 15
  • [ 2483-49-0 ]
  • [ 80143-17-5 ]
  • [ 18814-49-8 ]
  • 16
  • [ 18814-49-8 ]
  • cis-benzyl N-[(2R)-2-[((tert-butoxycarbonyl)amino)cyclopropyl]methoxy}propionyl]-L-alanyl-D-isoglutaminate [ No CAS ]
  • 17
  • [ 18814-49-8 ]
  • trans-benzyl N-[(2R)-2-[((tert-butoxycarbonyl)amino)cyclopropyl]methoxy}propionyl]-L-alanyl-D-isoglutaminate [ No CAS ]
  • 18
  • [ 18814-49-8 ]
  • cis-(2R)-2-[2-(acetylamino)cyclopropyloxy]-propionyl-L-alanyl-D-isoglutamine [ No CAS ]
  • 19
  • [ 18814-49-8 ]
  • cis-(2S)-2-[2-(acetylamino)cyclopropyloxy]-propionyl-L-alanyl-D-isoglutamine [ No CAS ]
  • 20
  • [ 18814-49-8 ]
  • trans-(2R)-2-[2-(acetylamino)cyclopropyloxy]-propionyl-L-alanyl-D-isoglutamine [ No CAS ]
  • 21
  • [ 18814-49-8 ]
  • trans-(2S)-2-[2-(acetylamino)cyclopropyloxy]-propionyl-L-alanyl-D-isoglutamine [ No CAS ]
  • 22
  • [ 18814-49-8 ]
  • (S,S)-(2R)-2-[2-(octanoylamino)cyclopropyloxy]propionyl-L-alanyl-D-isoglutamine [ No CAS ]
  • 24
  • [ 18814-49-8 ]
  • [ 682749-82-2 ]
  • 25
  • [ 18814-49-8 ]
  • [ 682747-36-0 ]
  • 27
  • [ 18814-49-8 ]
  • [ 682747-36-0 ]
  • 28
  • [ 18814-49-8 ]
  • [ 682749-76-4 ]
  • 29
  • [ 18814-49-8 ]
  • [ 682747-33-7 ]
  • 31
  • [ 18814-49-8 ]
  • [ 682747-33-7 ]
  • 32
  • [ 18814-49-8 ]
  • cis-(2S)-2-[2-(octanoylamino)cyclopropyloxy]propionyl-L-alanyl-D-isoglutamine [ No CAS ]
  • 33
  • [ 18814-49-8 ]
  • trans-(2S)-2-[2-(octanoylamino)cyclopropyloxy]propionyl-L-alanyl-D-isoglutamine [ No CAS ]
  • 34
  • [ 18814-49-8 ]
  • [ 682747-40-6 ]
  • 35
  • [ 18814-49-8 ]
  • [ 682747-40-6 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 18814-49-8 ]

Aryls

Chemical Structure| 53759-36-7

A407334 [53759-36-7]

Boc-Ala-D-Glu(OBzl)-OH

Similarity: 0.99

Chemical Structure| 868539-96-2

A131749 [868539-96-2]

(6S,9S,12S)-Methyl 12-benzyl-9-isobutyl-2,2-dimethyl-4,7,10-trioxo-6-phenethyl-3-oxa-5,8,11-triazatridecan-13-oate

Similarity: 0.90

Chemical Structure| 2766-17-8

A120188 [2766-17-8]

Z-Val-Gly-OEt

Similarity: 0.89

Chemical Structure| 2483-51-4

A154804 [2483-51-4]

Cbz-Ala-Ala-Ome

Similarity: 0.88

Chemical Structure| 1676-86-4

A461533 [1676-86-4]

(S)-Benzyl (4-(2,5-dioxooxazolidin-4-yl)butyl)carbamate

Similarity: 0.82

Amides

Chemical Structure| 53759-36-7

A407334 [53759-36-7]

Boc-Ala-D-Glu(OBzl)-OH

Similarity: 0.99

Chemical Structure| 868539-96-2

A131749 [868539-96-2]

(6S,9S,12S)-Methyl 12-benzyl-9-isobutyl-2,2-dimethyl-4,7,10-trioxo-6-phenethyl-3-oxa-5,8,11-triazatridecan-13-oate

Similarity: 0.90

Chemical Structure| 2766-17-8

A120188 [2766-17-8]

Z-Val-Gly-OEt

Similarity: 0.89

Chemical Structure| 2483-51-4

A154804 [2483-51-4]

Cbz-Ala-Ala-Ome

Similarity: 0.88

Chemical Structure| 1676-86-4

A461533 [1676-86-4]

(S)-Benzyl (4-(2,5-dioxooxazolidin-4-yl)butyl)carbamate

Similarity: 0.82

Esters

Chemical Structure| 53759-36-7

A407334 [53759-36-7]

Boc-Ala-D-Glu(OBzl)-OH

Similarity: 0.99

Chemical Structure| 868539-96-2

A131749 [868539-96-2]

(6S,9S,12S)-Methyl 12-benzyl-9-isobutyl-2,2-dimethyl-4,7,10-trioxo-6-phenethyl-3-oxa-5,8,11-triazatridecan-13-oate

Similarity: 0.90

Chemical Structure| 2766-17-8

A120188 [2766-17-8]

Z-Val-Gly-OEt

Similarity: 0.89

Chemical Structure| 2483-51-4

A154804 [2483-51-4]

Cbz-Ala-Ala-Ome

Similarity: 0.88

Chemical Structure| 1676-86-4

A461533 [1676-86-4]

(S)-Benzyl (4-(2,5-dioxooxazolidin-4-yl)butyl)carbamate

Similarity: 0.82